Ipsen announces positive results from Dysport study
Ipsen has announced positive results from its phase IIa clinical trial assessing Dysport® in the treatment of neurogenic…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
19 Mar 14
Ipsen has announced positive results from its phase IIa clinical trial assessing Dysport® in the treatment of neurogenic…
18 Feb 14
GlaxoSmithKline (GSK) has announced the start of a Phase III study to evaluate the efficacy and safety of…